A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous XMT-1001 in Patients With Advanced Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 27 Sep 2016
At a glance
- Drugs Camptothecin (Primary)
- Indications Gastric cancer; Non-small cell lung cancer; Oesophageal cancer; Solid tumours
- Focus Adverse reactions
- 19 Sep 2016 Status changed from active, no longer recruiting to completed.
- 03 Apr 2013 Planned end date changed from 1 Jun 2012 to 1 Jun 2013 as reported by ClinicalTrials.gov.
- 01 Mar 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.